Langue:

Vous quittez Lundbeck Suisse

Vous quittez maintenant lundbeck.com/ch. Veuillez noter que les informations de la page vers laquelle vous êtes redirigé peuvent ne pas être entièrement conformes aux exigences légales en Suisse, et que les informations relatives aux produits peuvent ne pas être entièrement conformes à l'information professionnelle suisse correspondante pour les médicaments. Toutes les informations doivent être discutées avec votre médecin et ne remplacent pas les conseils et le traitement de votre médecin.

elles sont transmises à

arrière

Conseil d'administration

Notre conseil d'administration

Le conseil d'administration est chargé d'approuver la stratégie de l'entreprise, de fixer les objectifs de la direction générale et d'évaluer les performances et les qualifications des cadres. En outre, le conseil d'administration assure des contrôles internes et externes adéquats. En bref, leur fonction est d'assurer une création de valeur durable pour toutes les parties prenantes de Lundbeck - les patients, les parties prenantes et nos employés.

Lars Søren Rasmussen

Chairman of the Board. Member, Audit Committee. Chairman, Remuneration & Nomination Committee. Born 1959.

Lars Søren Rasmussen, BSc Engineering and MBA, was born on 31 March 1959 and is a Danish citizen. He was nominated for election to H. Lundbeck A/S’ Board of Directors at the 2013 annual general meeting. He chairs H. Lundbeck A/S’ Remuneration & Nomination Committee and is a member of H. Lundbeck A/S' Audit Committee.

 

Lars Søren Rasmussen has considerable management experience in global med-tech. Lars Søren Rasmussen has most recently been CEO of Coloplast A/S from 2008 to 2018 and was a member of the company's executive management since 2001. During his time at Coloplast, Lars was responsible for various functions in the group, including global sales, innovation and production. He performed these duties from both Denmark and the US. Lars Rasmussen resigned his position as CEO of Coloplast A/S as of December 4th, 2018 and took over the position as Chairman of the Board of Directors of Coloplast A/S starting 5 December 5th.

 

Lars Søren Rasmussen's special qualifications for serving on H. Lundbeck A/S’ Board of Directors include his top management experience and knowledge of efficiency improvements and internationalisation.

 

Lars Søren Rasmussen is Chairman of the Board of Directors in Coloplast A/S, Chairman of the Board of Directors in AMBU A/S, Chairman of the Board of Directors in Igenomix S.L. and member of the Board of Directors of Demant A/S. 

Lene Skole-Sørensen

Deputy Chairman of the Board. Member, Remuneration & Nomination Committee. Member, Scientific Committee. Born 1959.

Lene Skole-Sørensen, BCom Finance, was born on 28 April 1959 and is a Danish citizen. She was nominated for election to H. Lundbeck A/S’ Board of Directors at the 2015 Annual General Meeting. She is a member of H. Lundbeck A/S’ Remuneration & Nomination Committee and Scientific Committee.

 

Lene Skole-Sørensen is CEO at the Lundbeck Foundation, CEO at Lundbeckfond Invest A/S and Chairman of the Board of Directors at LFI Equity A/S. Prior to joining the Lundbeck Foundation in 2014, Lene Skole-Sørensen was CFO at Coloplast A/S, where she was a member of the company’s executive management since joining in 2005. Lene Skole-Sørensen’s responsibilities included finance, IT, HR, communication, strategy and M&A. Before 2005, Lene Skole-Sørensen held various positions in the AP Moller-Maersk group, most recently as CFO of Maersk Company Ltd., London from 2000-2005.

 

Lene Skole-Sørensen’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include extensive knowledge and expertise within financing, strategy, business development and M&A as well as management experience from international companies including med-tech. 

 

Lene Skole-Sørensen is deputy Chairman of the Board of Directors of Ørsted A/S, Falck A/S, ALK-Abelló A/S, and member of the Board of Directors of Tryg A/S and Tryg Forsikring A/S.

Lars Erik Holmqvist

Member of the board. member, Audit Committee. Born 1959.

Lars Holmqvist, MSc in Business Administration, was born on 4 September 1959 and is a Swedish citizen. He was nominated for election to H. Lundbeck A/S' Board of Directors at the 2015 Annual General Meeting. He is a member of H. Lundbeck A/S' Audit Committee.

 

Lars Holmqvist was senior advisor within healthcare at Bain Capital Private Equity. He previously served as vice president responsible for sales and marketing at Pharmacia. In addition he has held management positions in several pharma and med-tech companies including Boston Scientific Corporation, Medtronic, Applied Biosystems Inc, DAKO A/S and Agilent Technologies.

 

Lars Holmqvist’s special qualifications for serving on H. Lundbeck A/S' Board of Directors include his international management experience, his expertise in finance, and his sales and marketing experience from the global pharmaceutical, med-tech and life-science industry.

 

Lars Holmqvist is Chairman of the Board of Directors for Biovica International AB and a member of the Board of Directors of the Lundbeck Foundation, ALK-Abelló A/S, Vitrolife AB, and Naka UK topco Ltd.

Jeremy Max Levin

member of the board. Chairman, Scientific Committee. Born 1953.

Jeremy Max Levin, BA Zoology, MA and DPhil in Molecular Biology and MB BChir Medicine and Surgery, was born on 9 September 1953 and is a British and US citizen. He was nominated for election to H. Lundbeck A/S’ Board of Directors at the 2017 Annual General Meeting. He chairs H. Lundbeck A/S’ Scientific Committee. 

 

Dr. Levin has more than 25 years of experience in the global pharmaceuticals industry, leading companies and people to develop and commercialize medicines that address compelling medical needs worldwide. Since 2014, he has been CEO and Chairman of Ovid Therapeutics, a New York based neurology company focused on rare and orphan diseases of the brain. Previously, Dr. Levin served as President & CEO of Teva Pharmaceuticals and before becoming CEO of Teva, he was a member of the Executive Committee of Bristol-Myers Squibb where he was globally responsible for overall strategy, alliances and business development. Prior to that, he was Global Head of Strategic Alliances at Novartis, where he established and managed strategic collaborations with multiple companies and research institutions around the world.

 

Dr. Levin’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include a robust blend of clinical insight and experience, business development skills, corporate strategy and financial savvy. In addition, he has substantial board experience.  

 

In addition to Ovid Therapeutics, Dr. Levin is member of the Board of Directors of BIO (the Biotechnology Innovation Organization based in the USA) and is Chairman of the Board of Directors of Opthea (based in Australia).

Jeffrey Berkowitz

member of the board. Member, Remuneration & Nomination Committee. Member, Scientific Committee. Born 1966.

Jeffrey Berkowitz, Juris Doctor and BA in Political Science, was born on 9 January 1966 and is a US citizen. He was nominated for election to the H. Lundbeck A/S’ Board of Directors at the 2018 Annual General Meeting and is a member of H. Lundbeck A/S' Scientific Committee and since March 2019 a member of the Remuneration & Nomination Committee.

 

Jeffrey Berkowitz is currently the CEO of Real Endpoints, a leader in the development and implementation of proprietary tools to strengthen market access for biopharmaceutical companies. Prior to this, Jeffrey Berkowitz has recently served as an Executive Vice President of UnitedHealth Group (UNH), and CEO of their Optum International subsidiary since 2016. He served as an Executive Committee member and President of Pharma & Global Market Access at Walgreens Boots Alliance, Inc. from 2014 and served first as Senior Vice President of Pharmaceutical Development and Market Access of Walgreen Co, then as President of Walgreens Boots Alliance Development in the period 2010 to 2015. From 1998 to 2010, he held a variety of positions with increasing responsibility in market access, sales and marketing with Schering-Plough prior to its acquisition by Merck in 2009. Prior to joining Schering-Plough, Jeffrey Berkowitz was a health care attorney for the international law firm Proskauer, LLP in New York and Washington, D.C.

 

Jeffrey Berkowitz’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include proven results and global experience with payers, pharmaceutical companies, specialty and retail pharmacies and drug distributors with deep experience in generic and branded procurement and inventory management, as well as pricing, reimbursement, specialty pharmacy distribution and health care strategies. He is a sought after thought leader and speaker in the area of pharmaceutical market access and reimbursement and has extensive public board and committee experience.

 

Jeffrey Berkowitz is an independent director of Esperion Therapeutics, Inc., and Chairman of the Board of PharmaTwoB. He is also a member of the Board of Directors of Zealand Pharma A/S, Uniphar PLC and Click Therapeutics. 

Dorothea Wenzel

member of the board. Chairman, Audit Committee. Born 1969.

Dorothea Wenzel holds a PhD in Health Economics & Macroeconomics and a M.Sc. in Business & Computer Sciences from the University of Darmstadt in Germany. She has also held fellowships at Harvard and was a visiting student at the University of California at Berkley. Dorothea Wenzel was born on 16 April 1969 and is a German citizen. She was nominated for election to H. Lundbeck A/S' Board of Directors at the 2021 Annual General Meeting. She chairs H. Lundbeck A/S' Audit Committee. 

 

Dorothea Wenzel is an independent Board member. She had a long career at Merck KGaA, headquartered in Darmstadt, Germany, where she most recently until August 2021 served as Executive Vice President and Head of the Global Business Unit Surface Solutions. In 2018 she was the CFO & Head of Strategy of the Performance Materials Division, from 2014 to 2018 she headed Merck’s Global Fertility Business Franchise, and from 2005 to 2013 she was the CFO of Merck’s Healthcare division. Prior to Merck she worked at McKinsey & Comp., with an e-commerce startup and for a German governmental commission.

 

Dorothea's special qualifications for serving on H. Lundbeck A/S’ Board of Directors include an impressive track record in Finance and Strategy leadership across multiple industries. Dorothea further strengthens the Board's competencies in finance and business transformation to ensure the company remains best set for the future. 

 

Dorothea Wenzel currently serves as a member on the Board of Directors of Dentsply Sirona Inc.

Santiago Arroyo

member of the board. member, Scientific committee. born 1960.

Dr. Santiago Arroyo, MD and PhD, was born in June 1960 and is a US citizen. He was nominated for election to H. Lundbeck A/S’ Board of Directors at the 2021 Annual General Meeting and is a member of H. Lundbeck's A/S' Scientific Committee. 

 

Dr. Arroyo has more than 30 years of experience in academic neurology and pharmaceutical research and development. As an academic neurologist, Dr. Arroyo held faculty positions at the Johns Hopkins Hospital, Hospital Clinic of Barcelona and the Medical College of Wisconsin where he was Associate Professor of Neurology. He has special expertise in pediatric and adult epilepsy and electrophysiology. In 2003, Dr. Arroyo joined the pharmaceutical industry and has held a variety of positions in clinical research and development - most recently as Chief Medical Officer of Momenta Pharmaceuticals, a biotechnology company located in Massachusetts, USA, focusing on discovering and developing novel therapeutics to treat rare, immune-mediated diseases. Prior to this, Dr. Arroyo served as Chief Medical Officer of Boston Pharmaceuticals, held roles of Senior Vice President, Head of Clinical Research and Chief Medical Officer of Biotherapeutics and Pharmatherapeutics at Pfizer Inc., Therapeutic Area Head for Neurosciences, Discovery Medicine and Clinical Pharmacology at Bristol-Myers Squibb and Neurology Global Therapeutic Area Head for Eisai Global Clinical Development.

 

Dr. Arroyo’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include his therapeutic and deep scientific expertise in neuroscience and beyond as well as strategic and business vision. 

 

Santiago Arroyo serves as member the Board at Marinus Pharmaceuticals, headquartered in the U.S.

Hossein Armandi

Employee Representative (2022-2026). SENIOR TECHNICIAN. BORN 1962.

Hossein Armandi, Process Technologist, was born in 1962 and is a Danish citizen. He has been employed at Lundbeck since 1995, holds a position as Senior Technician and currently works in the research area department of translational Drug Metabolism and Pharmacokinetics.

Dorte Clausen

EMPLOYEE REPRESENTATIVE (2022-2026). PRINCIPAL CLINICAL STUDY MANAGER PSYCHIATRY. BORN 1984.

Dorte Clausen, M.Sc. Molecular Biomedicine, was born in 1984 and is a Danish citizen. She has been employed at Lundbeck since 2012. She currently manages clinical studies within psychiatry and holds a position as Principal Clinical Study Manager.

 

Dorte is also a member of the Board at a Danish Union Pharmadanmark as well as member of the Board at training & conference center Pharmakon.

Lasse Skibsbye

EMPLOYEE REPRESENTATIVE (2022-2026). PRINCIPLE SCIENTIST. BORN 1983.

Lasse Skibsbye, Pharmacist and PhD in Medicine with specialty in cardiovascular safety pharmacology, was born in 1983 and is a Danish citizen.

 

He has been employed at Lundbeck since 2016 and currently holds a position as Principal Scientist and Safety Pharmacologist in the department of Exploratory Toxicology, Non-clinical Safety Research.

 

Lasse is also a member of the Board in Safety Pharmacology Society.

Camilla Gram Andersson

EMPLOYEE REPRESENTATIVE (2022-2026). DIRECTOR CORPORATE HEALTH, SAFETY & ENVIRONMENT. BORN 1972.

Camilla Gram Andersson, M.Sc. in civil engineering, was born in 1972 and is a Danish citizen.

 

She has been employed at Lundbeck since 2005 and currently heads up Corporate Health, Safety & Environment (HSE) department, where she is responsible for the development of Lundbeck’s HSE strategy.

 

Camilla is also a member of the Sector Working Environment Council of Danish Industries (DI) as well as member of the HSE expert group in European Federation of Pharmaceutical Industries and Associations (EFPIA).

plus de Lundbeck